IRIS
BARCHIESI, Francesco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.347
EU - Europa 3.622
AS - Asia 1.681
SA - Sud America 234
AF - Africa 80
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 11.974
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.301
UA - Ucraina 766
SG - Singapore 522
IE - Irlanda 454
RU - Federazione Russa 448
TR - Turchia 433
IT - Italia 405
DE - Germania 381
SE - Svezia 367
DK - Danimarca 281
HK - Hong Kong 250
CN - Cina 233
BR - Brasile 212
FI - Finlandia 184
KR - Corea 151
GB - Regno Unito 146
FR - Francia 116
CI - Costa d'Avorio 56
IN - India 28
CA - Canada 26
IR - Iran 24
NL - Olanda 18
MX - Messico 16
BE - Belgio 15
AT - Austria 13
EC - Ecuador 7
MA - Marocco 7
PL - Polonia 7
ZA - Sudafrica 7
AR - Argentina 6
EU - Europa 6
BD - Bangladesh 5
PK - Pakistan 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
AU - Australia 3
EG - Egitto 3
ES - Italia 3
JP - Giappone 3
NP - Nepal 3
PT - Portogallo 3
PY - Paraguay 3
CM - Camerun 2
ID - Indonesia 2
KE - Kenya 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LT - Lituania 2
MD - Moldavia 2
PE - Perù 2
VE - Venezuela 2
A1 - Anonimo 1
AL - Albania 1
BB - Barbados 1
BG - Bulgaria 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
JM - Giamaica 1
KH - Cambogia 1
KW - Kuwait 1
PS - Palestinian Territory 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TW - Taiwan 1
UY - Uruguay 1
VN - Vietnam 1
Totale 11.974
Salva come PNG Salva come JPEG
Città #
Jacksonville 789
Fairfield 738
Chandler 532
Dublin 449
Boardman 418
Ashburn 359
Wilmington 312
Singapore 299
Woodbridge 299
Seattle 252
Hong Kong 245
Houston 244
Des Moines 242
Cambridge 239
New York 211
Ann Arbor 192
Lawrence 172
Princeton 172
San Mateo 171
Moscow 108
Turin 102
San Diego 98
Abidjan 56
The Dalles 56
Centro 51
Beijing 48
Munich 43
Redmond 41
London 28
Shanghai 23
Los Angeles 22
Helsinki 21
Ancona 19
Norwalk 18
Washington 18
Turku 17
Marche 16
Nuremberg 16
Ottawa 16
Dallas 15
Brussels 14
Guangzhou 14
Kilburn 13
São Paulo 12
Wuhan 12
Pune 11
Milan 10
Bologna 9
Izmir 8
Bari 7
Brooklyn 7
Rome 7
San Francisco 7
Santa Clara 7
Belo Horizonte 6
Falls Church 6
Ferrara 6
Porto Alegre 6
Rio de Janeiro 6
Andover 5
Atlanta 5
Brasília 5
Jiaxing 5
Paris 5
Prescot 5
San Severino Marche 5
Tashkent 5
Vienna 5
Wuxi 5
Acton 4
Ankara 4
Auburn Hills 4
Chiswick 4
Curitiba 4
Falconara Marittima 4
Fayetteville 4
Hanover 4
Jinhua 4
Johannesburg 4
Mexico City 4
Pesaro 4
Sarajevo 4
Seoul 4
Shenzhen 4
Amsterdam 3
Appignano 3
Baku 3
Betim 3
Boston 3
Campinas 3
Chicago 3
Cingoli 3
Delhi 3
Dourados 3
Fortaleza 3
Franca 3
Goiânia 3
Guayaquil 3
Heze 3
Hounslow 3
Totale 7.493
Salva come PNG Salva come JPEG
Nome #
Antimicrobial Resistance: A Challenge for the Future 187
Invasive Aspergillosis in liver transplant recipients: Epidemiology, clinical characteristics, treatment, and outcomes in 116 cases 128
Delay of antifungal therapy influences the outcome of invasive aspergillosis in experimental models of infection 118
Candida guilliermondii fungemia in patients with hematologic malignancies. 114
Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014 113
Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU 112
Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. 111
Trichosporon beigelii fungaemia in an AIDS patient. 111
Antimicrobial activity of polycationic peptides 107
Epidemiology and outcome of systemic infections due to saprochaete capitata: case report and review of the literature 107
Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. 106
Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes 105
Anidulafungin in combination with amphotericin B against Aspergillus fumigatus. 104
Species distribution and antifungal susceptibilities of bloodstream Candida isolates: a nine-years single center survey 102
In-vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. 101
Changing characteristics and risk factors of patients with and without incident HCV infection among HIV-infected individuals 101
Comparison of three methods for testing azole susceptibilities of Candida albicans strains isolated sequentially from the oral cavities of aids patients. 100
In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp. 100
Activity of buforin II alone and in combination with azithromycin and minocycline against Cryptosporidium parvum in cell culture. 99
Sequential therapy with caspofungin and fluconazole for Candida albicans infection. 98
Comparison of liver fibrosis progression in HIV/HCV co-infected and HCV mono-infected patients by transient elastometry 98
Characterisation of candidemia in patients with recent surgery: A 7-year experience 98
Carbapenem-Resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients 96
High rate of ceftobiprole resistance among clinical methicillin-resistant Staphylococcus aureus isolates from a hospital in central Italy 96
An (Italian) proposal for a comprehensive approach to infections across the surgical pathway 96
Posaconazole against Candida glabrata isolates with various susceptibilities to fluconazole. 95
Prevalence and predictors of malignancies in a polycentric cohort of HIV patients from Italy 94
Epidemiology and microbiology of surgical wound infections. 92
Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. 90
ACTIVITY OF THE NEW ANTIFUNGAL TRIAZOLE, POSACONAZOLE, AGAINST CRYPTOCOCCUS NEOFORMANS 90
Analysis of antibody response to Cryptococcus neoformans in five patients with AIDS and cryptococcosis by immunoblotting. 90
Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). 89
In-vitro activity of rifabutin and albendazolo singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. 89
In vitro activities of voriconazole in combination with other three antifungal agents against Candida glabrata 88
Evaluation of the disk diffusion method compared to the microdilution method in susceptibility testing of anidulafungin against filamentous fungi. 87
Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata 87
In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp. 85
Heterozygosis and pathogenicity of Cryptococcus neoformans AD-hybrid isolates. 84
Reply to Ma et al.: Osteomyelitis caused by aspergillus species 83
In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. 82
Clinical and epidemiological characteristics of KPC-producing Klebsiella pneumoniae from bloodstream infections in a tertiary referral center in Italy 82
Evaluating Liver Fibrosis by Transient Elastometry in Patients With HIV-HCV Coinfection and Monoinfection. 81
Epidemiology of onychomycosis and paronychia in the area of ANCONA (ITALY) over a period of 5 years 80
In vitro activity of the lipopeptide derivative (Pal-Lys-Lys-NH), alone and in combination with antifungal agents, against clinical isolates of dermatophytes. 80
Factors related to outcome of bloodstream infections due to Candida parapsilosis complex 80
Candidemia in intensive care units over nine years at a large Italian university hospital: Comparison with other wards 80
Candidemia in Internal Medicine: Facing the New Challenge 80
Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis. 79
Infection due to Absidia corymbifera in a patient with a massive crush trauma of the foot 77
Aspergillus spp invasive external otitis: favourable outcome with a medical approach 77
Anticryptosporidial activity of ranalexin, lasalocid and azithromycin alone and in combination in cell lines. 77
In vitro activity of the protegrin IB-367 alone and in combination compared with conventional antifungal agents against dermatophytes 76
How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in Aspergillus fumigatus isolates using four-well azole-containing agar plates 76
ELECTROPHORETIC KARYOTYPING AND TRIAZOLE SUSCEPTIBILITY OF CANDIDA GLABRATA CLINICAL ISOLATES 75
Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans. 75
In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents. 75
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial 75
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 75
In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens 74
Osteomyelitis caused by Aspergillusspecies: a review of 310 reported cases 74
Acute histoplasmosis in immunocompetent travelers: a systematic review of literature 74
EUCAST technical note on posaconazole. 73
Anticryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems. 73
Bloodstream infections in the COVID-19 era: results from an Italian multi-centre study 73
In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans. 72
In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. 71
EUCAST Technical Note on voriconazole. 71
In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles. 71
Interactions of Posaconazole and Flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother. 71
Central venous catheter unrelated candidemia influences the outcome of infection in patients with solid tumors 71
Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. 70
In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. 70
Posaconazole prophylaxis in experimental systemic zygomycosis. 69
Caspofungin in combination with amphotericin B against Candida parapsilosis. 69
Antifungal susceptibility patterns of yeast isolates causing bloodstream infections. 69
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abacavir: a case report. 69
Clinical efficacy and tolerability of caspofungin in a renal transplant patient with Aspergillus flavus lung infection: case report. 69
Comparison of four methods for DNA typing of clinical isolates of Candida glabrata. 68
In vitro and in vivo effects of echinocandins against Candida parapsilosis sensu stricto, Candida orthopsilosis and Candida metapsilosis. 67
Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. 67
EUCAST technical note on Amphotericin B 67
Ceftazidime-Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study 67
In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. 66
Interactions of posaconazole and flucytosine against Cryptococcus neoformans. 66
In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata. 66
Caspofungin in combination with amphotericin B against Candida glabrata. 66
Disruption of homocitrate synthase genes in Candida albicans affects growth but not virulence. 66
International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. 66
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. 65
Comparison between disk diffusion and microdilution methods for determining susceptibility of clinical fungal isolates to caspofungin. 65
Voriconazole and multidrug resistance in Candida albicans. 64
Tolerance to amphotericin B in clinical isolates of Candida tropicalis. 64
Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. 64
Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates 64
Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection. 64
Prevalence and predictors of malignancies in HIV patients: results of a retrospective multicentric Italian cohort. 64
In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus. 63
EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. 63
In vitro activity of Tachyplesin III alone and in combination with terbinafine against clinical isolates of dermatophytes. 63
Efficacy of caspofungin against Aspergillus terreus 63
Totale 8.284
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.849
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.849
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020237 0 0 0 0 0 0 0 0 0 0 0 237
2020/20212.614 148 271 352 48 301 190 252 158 222 278 286 108
2021/20221.512 133 430 13 42 20 63 116 70 76 136 154 259
2022/20232.053 214 170 149 112 134 353 13 95 556 11 173 73
2023/20241.287 213 25 67 238 246 277 25 18 15 14 15 134
2024/20252.272 210 202 166 27 60 59 166 111 605 161 236 269
Totale 12.186